Skip to main content
Fig. 2 | Trials

Fig. 2

From: Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin

Fig. 2

Schedule of screening, randomization, interventions and assessment of the patients in the BLMs4BU study. AEs, adverse events; BUFLS, Buruli Ulcer Functional Limitation Score; FNA, fine-needle aspiration; M, month; HIV, human immunodeficiency virus; PCR, polymerase chain reaction; RC8, 8 weeks of rifampicin-clarithromycin; RCA4, 4 weeks of rifampicin-clarithromycin plus amoxicillin/clavulanate; SAEs, serious adverse events; W, week. *PK analysis (blood samples). It will be performed between days 7 and 14 after starting the treatment, prior to the second daily dose of CLA and AMX/CLV. Sampling times will include a pre-dose at time 0 (within 10 min pre-dose) and at times 0.5, 1, 1.5, 2, 2.5, 3, 5, 7.5, and 10 h post-dose

Back to article page

Trials

ISSN: 1745-6215